Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × abiraterone × Tumor-Agnostic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 8 Tumor-Agnostic 1 Plasma cell 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Gastrointestinal 1 Classical hematology 1 Breast 1

Conditions

Neoplasms 2 Neoplasm Metastasis 1

Interventions

pembrolizumab 32 Specimen Handling 26 Magnetic Resonance Spectroscopy 25 Biopsy 25 Radiosurgery 24 Nivolumab 21 Gemcitabine 19 Paclitaxel 18 Carboplatin 14 Trastuzumab 13 Bevacizumab 12 Irinotecan 11 Everolimus 11 Capecitabine 10 130-nm albumin-bound paclitaxel 10 trastuzumab deruxtecan 9 Radiotherapy 9 Ipilimumab 9 Albumin-Bound Paclitaxel 9 atezolizumab 8 Taxes 8 Sorafenib 8 Erlotinib Hydrochloride 8 Docetaxel 8 olaparib 7 abemaciclib 7 Standard of Care 7 Oxaliplatin 7 Fluorouracil 7 Drug Therapy 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03295565 2022-04-15

OSTRICh

The Netherlands Cancer Institute

Phase 2/3 Completed

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡